OVID Stock Analysis: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$2.22
-0.15 (-6.33%)
▼
5d:
-4.72%
30d:
-17.16%
90d:
-19.86%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 12, 2026
8d
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $2.22, which is considered oversold relative to its 30-day fair value range of $2.32 to $2.63.
Technical Outlook: Technically, OVID is in a strong uptrend. The price is currently testing key support at $2.20. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: OVID has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.47 (+146.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OVID is in a strong uptrend. The price is currently testing key support at $2.20. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: OVID has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.47 (+146.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.32 -
$2.63
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 146.4% below Wall St target ($5.47)
Trading Range Analysis
30-Day Trading Range
$2.32 -
$2.63
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.20
Resistance Level
$2.52
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.91
Wall Street Target
$5.47
(+146.4%)
Revenue Growth (YoY)
844.7%
Share & Embed Analysis
Last updated: August 03, 2026 3:06 AM ET
Data refreshes hourly during market hours. Next update: 4:06 AM
Data refreshes hourly during market hours. Next update: 4:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
